China’s National Health Commission (NHC) has released the second national drug use monitoring list, covering 30 drugs. Local bureaus are required to formulate and improve clinical application guidelines for these drugs, clarify the conditions and principles of clinical application, and strengthen the supervision of rational drug use.
First List and Overlapping Drugs
The NHC released the first such list in July 2019, which included five drugs that are also present in the second list: oxiracetam, ossotide, cerebroprotein hydrolysate, alprostadil, and edaravone. According to the NHC, drugs included in both lists will see intensified monitoring. Meanwhile, drugs that were included in the first list but not the second can be exempt from monitoring after continuous monitoring for at least one year.
Future Outlook
With the release of the second monitoring list, the NHC aims to enhance the rational use of drugs in clinical settings. This initiative underscores the government’s commitment to improving drug safety and efficacy, ensuring that medications are used appropriately and effectively in healthcare settings.-Fineline Info & Tech
